


I. Epidemiological profile

Population (UN)	2015	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	17,200,000	100	Plasmodium species: <i>P. falciparum</i> (100%), <i>P. vivax</i> (0%)
Low transmission (0-1 cases per 1000 population)	0	-	Major anopheles species: <i>An. funestus</i> , <i>An. gambiae</i> , <i>An. arabiensis</i>
Malaria-free (0 cases)	0	-	Reported confirmed cases (health facility): 3,661,238 Estimated cases: 3,300,000 [2,400,000 ; 4,200,000]
Total	17,220,000		Confirmed cases at community level: 197,354 Reported deaths: 3,799 Estimated deaths: 7,200 [1,800 ; 10,000]

II. Intervention policies and strategies


Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2006	First-line treatment of unconfirmed malaria	AL	2007					
	ITNs/ LLINs distributed to all age groups	Yes	2010	First-line treatment of <i>P. falciparum</i>	AL	2007					
IRS	IRS is recommended	Yes	2007	Treatment failure of <i>P. falciparum</i>	AS+AQ	2007					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS; QN	2007					
Larval control	Use of larval control recommended	No	-	Treatment of <i>P. vivax</i>	-	-					
IPT	IPT used to prevent malaria during pregnancy	Yes	1993	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		-					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2011	Type pf RDT used		P.f only					
	Malaria diagnosis is free of charge in the public sector	No	-								
Treatment	ACT is free of charge for all ages in public sector	Yes	2007	Therapeutic efficacy tests (clinical and parasitological failure, %)							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Is banned	2011	Medicine	Year	Min	Median	Max	Follow-up	No of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-	AL	2005-2014	0	4.3	19.5	28 days	11	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	No	-	AS+AQ	2005-2014	0	1.5	3.6	28 days	4	<i>P. falciparum</i>
	G6PD test is a requirement before treatment with primaquine	No	-								
	Directly observed treatment with primaquine is undertaken	No	-								
System for monitoring adverse reactions to antimalarials exists	No	2007									
Surveillance	ACD for case investigation (reactive)	No	-	Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)							
	ACD of febrile cases at community level (pro-active)	No	-	Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested		
	Mass screening is undertaken	No	-	2010-2014	Yes	No	Yes	No	An. funestus s.l., An. funestus s.s., An. gambiae s.l.		
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	-	-								
Case reporting from private sector is mandatory	No	-									

III. Financing




Government expenditure by intervention in 2015


IV. Coverage




Cases tested and treated in public sector




V. Impact



Test positivity



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths (per 100 000)

